NCT03337087 - Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 2, 2018

Primary Completion Date

March 31, 2021

Study Completion Date

August 9, 2025

Conditions

Metastatic Biliary Tract CarcinomaMetastatic Colorectal CarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaMetastatic Malignant Digestive System NeoplasmMetastatic Pancreatic AdenocarcinomaStage IV Colorectal Cancer AJCC v7Stage IV Pancreatic Cancer AJCC v6 and v7Stage IVA Colorectal Cancer AJCC v7Stage IVB Colorectal Cancer AJCC v7

Interventions

DRUG

Fluorouracil

Given IV

DRUG

Irinotecan Sucrosofate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Leucovorin Calcium

Given IV

DRUG

Rucaparib

Given PO

Trial Locations (3)

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

55905

Mayo Clinic in Rochester, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER